Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are ... seeking to invalidate three GSK patients covering its RSVPreF3 shot ...

Pfizer’s (NYSE:PFE) respiratory syncytial virus (RSV) vaccine Abrysvo was well-tolerated and generated strong neutralizing ...

Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a similar approach in respiratory syncytial virus (RSV). The drugmaker is in the ...

"Pfizer reports top-line results from Phase III RSV vaccine trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been ...

Drug company Pfizer is seeking to expand the approval of its respiratory syncytial virus (RSV) vaccine to include adults over the age of 18.

Vincenza Snow, MD, Senior Director, Pfizer Medical Affairs joined us to talk about RSV today. RSV (respiratory syncytial virus) is a highly contagious respiratory virus, meaning it can spread ...